Upcoming, highly-anticipated gene therapies for progressive muscle-degenerating disease Duchenne muscular dystrophy (DMD) will cost a whopping $2 million per patient per year—double the cost of the current standard-of-care, exon-skipping therapies—says GlobalData. The leading data and analytics company’s research highlighted the costs of various DMD treatment types as part of an assessment of the upcoming pipeline, […]

Johnson & Johnson’s (J&J’s) COVID-19 vaccine sales are forecast to consistently decline between 2022 and 2027, according to GlobalData, largely due to competition from Pfizer. The leading data and analytics company’s forecast for J&J decreased by an average of 35% from Q3 2021 to Q4 2021, and is now expected to generate $6.7 billion in […]

Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin. It is an X-linked recessive disorder mainly affecting males, that causes muscles to be fragile and easily damaged. DMD is progressive and most affected individuals require a wheelchair by adolescence. […]

The bipolar disorder pipeline is moderate in size containing agents in a range of different drug classes, including both tried and tested, and novel classes. However, it is unlikely that any product in the late-stage pipeline will be able to displace lithium as the gold standard of treatment, says GlobalData, a leading data and analytics […]

In light of National Thyroid Awareness Month, GlobalData highlights that the lack of awareness around hypothyroidism (also known as ‘underactive thyroid’) is impacting diagnosis rates and limiting investment. The leading data and analytics company notes that only 14%* of Phase I-III clinical trials for hypothyroidism in the last five years were sponsored by pharma companies. […]

Less than 5%* of adults with overactive bladder (OAB) are currently managed with drug therapy due to a combination of low diagnosis rates and the poor risk-benefit ratio of available treatments, according to GlobalData. The leading data and analytics company notes that, despite this surprisingly low number and the clear need for new therapies, the […]